13F Holdings
中文EN

VREOF Vireo Growth Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1771706 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY255.9%
TTM net income YoY-2.2%
TTM EPS YoY149.6%
Revenue 3-yr CAGR101.0%
Net income 3-yr CAGR—

Margins

Gross margin47.4%
Operating margin1.3%
Net margin-9.6%
FCF margin-14.6%
EBITDA margin5.4%

Returns

ROE-17.5%
ROA-6.2%
ROIC (approx.)3.3%
Asset turnover0.64x

Leverage & solvency

Liabilities / assets65.3%
Debt / equity0.00x
Current ratio1.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.58x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue20.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$268.77M$99.38M$88.13M$74.63M$54.45M
Cost of revenue———$39.42M$32.01M
Gross profit$127.10M$50.77M$44.10M$30.91M$19.80M
SG&A expense$81.19M$28.06M$28.22M$33.82M$33.66M
Operating income-$1.05M$13.56M$10.58M-$6.94M-$20.48M
Interest expense—$31.19M$31.26M$22.59M$10.58M
Pretax income-$39.91M-$16.89M-$17.82M-$36.56M-$29.57M
Income tax$28.23M$11.11M$7.72M$5.89M$4.12M
Net income-$68.11M-$28.01M-$25.55M-$42.46M-$33.69M
EBITDA$15.06M$16.10M$13.45M-$3.60M-$17.45M
EPS (basic)-0.09-0.16-0.19-0.33-0.27
EPS (diluted)-0.09-0.16-0.19-0.33-0.27
Weighted avg. shares (diluted)734.74M180.39M135.24M128.13M123.81M
Banking
Loans, net——$3.75M$3.75M—
Balance sheet
Cash & equivalents$122.50M$91.60M$15.96M$15.15M$15.16M
Short-term investments$1.00M————
Receivables$12.70M$2.87M$2.26M$4.29M$4.50M
Inventory$60.00M$21.67M$19.29M$20.51M$20.42M
Current assets$305.10M$230.37M$148.85M$46.73M$41.64M
PP&E, net$217.50M$32.31M$23.29M$89.61M$99.49M
Goodwill$87.50M$0$0$183,836$183,836
Intangibles$117.50M$7.90M$8.72M$8.78M$10.18M
Total assets$817.20M$278.86M$183.26M$159.16M$166.97M
Current liabilities$191.70M$135.47M$179.47M$29.71M$16.41M
Short-term debt———$11.78M—
Long-term debt———$46.25M$27.33M
Total debt———$58.03M$27.33M
Total liabilities$509.80M$223.30M$199.31M$155.72M$123.96M
Shareholders' equity$307.40M$55.50M-$16.04M$3.44M$43.01M
Net debt———$42.88M$12.17M
Cash flow statement
Operating cash flow$3.71M-$10.23M-$965,906-$18.07M-$30.52M
Capital expenditure$28.32M$11.69M$4.96M$5.56M$18.04M
Free cash flow-$24.61M-$21.93M-$5.93M-$23.63M-$48.56M
Investing cash flow$8.76M-$8.13M-$3.48M-$5.62M-$7.21M
Financing cash flow$18.42M$94.01M$5.26M$23.68M$25.78M
Depreciation & amortization$16.11M$2.54M$2.87M$3.34M$3.03M
Stock-based compensation$18.66M$3.63M$4.16M$2.69M$5.18M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.